Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
A legfontosabb adatok
- Ki végzi
- Arrowhead Pharmaceuticals
- Hol
- Ann Arbor, Greensboro, Indianapolis, Kansas City, Los Angeles, Mesquite, New Haven, New York, North Platte, Philadelphia, Pittsburgh, San Antonio, Santa Clarita, Seattle, Springfield, St Louis és Wilmington (Egyesült Államok)Mind a 17 helyszín megnézéseMég 28 másik országban, 119 helyszínen
- Azonosító
- Állapot
- Toboroz
- Fázis
- 3. fázis
- Résztvevők
- 288 fő, tervezett
- Kezdés
- 2025. ápr. 24.
- Várható befejezés
- 2029. jún.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoport
- A vizsgált kezelések
- Plozasiran
- Placebo
- A regiszteradat frissítve
- 2026. szeptember 21.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 22 feltétel megnézéseKevesebb
Ki vehet részt
- Males, or nonpregnant (who do not plan to become pregnant) nonlactating females
- Established diagnosis of SHTG and prior documented evidence of fasting TG levels of ≥ 880 mg/dL (≥ 10 mmol/L)
- Documented evidence of at least 1 prior AP event not attributed to other etiologies occurring within the last 60 months prior to Screening
- Fasting low-density lipoprotein cholesterol (LDL-C) ≤ 130 mg/dL (≤ 3.37 mmol/L) at Screening
- Screening hemoglobin A1c (HbA1c) ≤ 9.5%
- Willing to follow diet counseling and maintain a stable low-fat diet
- Must be on standard of care lipid and TG-lowering medications per local guidelines (unless documented as intolerant, or a treatment failure as determined by the Investigator)
Ki nem vehet részt
- Use of any hepatocyte-targeted small interfering ribonucleic acid (siRNA) that targets lipids and/or triglycerides within 365 days before Day 1, except inclisiran
- AP ≤ 4 weeks prior to Randomization/Day 1
- Any planned bariatric surgery or similar procedures to induce weight lost starting at consent through End of Study (EOS)
- History of pacemaker or automatic implantable cardioverter defibrillators implant within 30 days before Screening
- Planned coronary intervention (e.g. stent placement or heart bypass) during the study
- History of arterial revascularization within 16 weeks of Screening
- History of acute coronary syndrome event within 24 weeks of Screening
- Recent atherosclerotic cardiovascular disease (ASCVD) event within 24 weeks of Screening
- Recent unstable or symptomatic cardiac arrhythmia (including any associated medication changes) within 90 days of Screening. Individuals with stable well-controlled atrial arrhythmia will be allowed to participate in the study
- Current diagnosis of nephrotic syndrome
- New York Heart Association Class III-IV heart failure or last known ejection fraction of < 30%
- Chronic kidney disease, defined by an estimated glomerular filtration rate (eGFR) < 20 mL/min/1.73 m\^2
- Liver disease defined as cirrhosis or Child-Pugh Class B and C, or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5× Upper Limit of Normal (ULN) at Screening; Note: Additional Inclusion/Exclusion Criteria may apply per protocol
- Use of any other hepatocyte targeted siRNA or antisense oligonucleotide molecule within 60 days or within 5 half-lives lives before day 1. Whichever is longer
- Body mass index (BMI) > 45 kg/m\^2
Helyszínek itt: Egyesült Államok
Még 28 másik országban, 119 helyszínen
- Ann Arbor, MichiganHospital not named in the registryContact: Medical MonitorRésztvevőt keres
- Greensboro, North CarolinaHospital not named in the registryContact: Medical MonitorRésztvevőt keres
- Indianapolis, IndianaHospital not named in the registryContact: Medical MonitorRésztvevőt keres
- Kansas City, MissouriHospital not named in the registryContact: Medical MonitorRésztvevőt keres
- Los Angeles, CaliforniaHospital not named in the registryContact: Medical MonitorRésztvevőt keres
- Mesquite, TexasHospital not named in the registryContact: Medical MonitorRésztvevőt keres
- New Haven, ConnecticutHospital not named in the registryContact: Medical MonitorRésztvevőt keres
- New YorkHospital not named in the registryContact: Medical MonitorRésztvevőt keres
- North Platte, NebraskaHospital not named in the registryContact: Medical MonitorRésztvevőt keres
- Philadelphia, PennsylvaniaHospital not named in the registryContact: Medical MonitorRésztvevőt keres
- Pittsburgh, PennsylvaniaHospital not named in the registryContact: Medical MonitorRésztvevőt keres
- San Antonio, TexasHospital not named in the registryContact: Medical MonitorRésztvevőt keres
- Santa Clarita, CaliforniaHospital not named in the registryContact: Medical MonitorRésztvevőt keres
- Seattle, WashingtonHospital not named in the registryContact: Medical MonitorRésztvevőt keres
- Springfield, IllinoisHospital not named in the registryContact: Medical MonitorRésztvevőt keres
- St Louis, MissouriHospital not named in the registryContact: Medical MonitorRésztvevőt keres
- Wilmington, North CarolinaHospital not named in the registryContact: Medical MonitorRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
This study will evaluate the efficacy and safety of plozasiran in approximately 288 adult participants with severe hypertriglyceridemia (SHTG) and history of at least two prior acute pancreatitis (AP) events not attributed to other etiologies, with at least one occurring within the last 12 months prior to screening. Eligible participants will be randomly assigned in a double-blind manner to either receive plozasiran 25 mg by subcutaneous (SC) injection every three months (Q3M) or matching placebo. Enrolled participants will be counseled to remain on the specified low-fat diet and background medications throughout the study. Following completion of the double-blind treatment period, or if the participant has a positively adjudicated AP event (whichever occurs first), participants will transition to the 12-month Open-Label Extension (OLE) treatment period receiving plozasiran 25 mg by SC injection Q3M.
A vizsgálat 2 csoportja
- Plozasiran InjectionA vizsgált kezelés
Plozasiran by SC injection every 3 months (Q3M) through completion of the randomized period Plozasiran by SC injection Q3M through completion of the OLE period
Kezelés: Plozasiran
- PlaceboA vizsgált kezelés
calculated volume to match active treatment by SC injection (randomized period)
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- Hivatalos cím
- Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis (SHASTA-5 Study)
- A regiszteradat frissítve
- 2026. szeptember 21.